期刊文献+

特殊人群慢性乙型肝炎抗病毒治疗研究进展 被引量:1

下载PDF
导出
摘要 近年来,随着慢性乙型肝炎(CHB)抗病毒治疗研究的不断进展和相关指南的更新,普通人群CHB的抗病毒治疗已越来越规范化。然而由于循证医学证据不足,各指南相关推荐的证据级别较低,特殊人群CHB患者的抗病毒治疗已成为临床治疗的难点和研究的热点。现就特殊人群CHB的治疗最新研究成果综述如下。
出处 《肝脏》 2015年第9期728-732,共5页 Chinese Hepatology
基金 上海市科委"科技创新行动计划"医学与农业领域重点项目(13401902100) 上海市卫生局临床医学应用研究项目(20114279)
  • 相关文献

参考文献7

二级参考文献83

  • 1Iloeje UH,Yang HI,Su J,陆伟(摘译),张占卿(审校).根据循环乙型肝炎病毒载量预测肝硬化的危险性[J].世界感染杂志,2006,6(4):396-396. 被引量:211
  • 2European Association for the Study of the Liver.EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection[J]Journal of Hepatology,2012(1).
  • 3Yun-Fan Liaw,Nancy Leung,Jia-Horng Kao,Teerha Piratvisuth,Edward Gane,Kwang-Hyub Han,Richard Guan,George K. K. Lau,Stephen Locarnini.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update[J]. Hepatology International . 2008 (3)
  • 4Chuen–Fei Chen,Wen–Chung Lee,Hwai–I. Yang,Hung–Chuen Chang,Chin–Lan Jen,Uchenna H. Iloeje,Jun Su,Chuhsing K. Hsiao,Li–Yu Wang,San–Lin You,Sheng–Nan Lu,Chien–Jen Chen.Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma[J]. Gastroenterology . 2011 (4)
  • 5Erik H.C.J. Buster,Bettina E. Hansen,George K.K. Lau,Teerha Piratvisuth,Stefan Zeuzem,Ewout W. Steyerberg,Harry L.A. Janssen.Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa[J]. Gastroenterology . 2009 (6)
  • 6Giovanni Raimondo,Jean-Pierre Allain,Maurizia R. Brunetto,Marie-Annick Buendia,Ding-Shinn Chen,Massimo Colombo,Antonio Craxì,Francesco Donato,Carlo Ferrari,Giovanni B. Gaeta,Wolfram H. Gerlich,Massimo Levrero,Stephen Locarnini,Thomas Michalak,Mario U. Mondelli,Jean-Michel Pawlotsky,Teresa Pollicino,Daniele Prati,Massimo Puoti,Didier Samuel,Daniel Shouval,Antonina Smedile,Giovanni Squadrito,Christian Trépo,Erica Villa,Hans Will,Alessandro R. Zanetti,Fabien Zoulim.Statements from the Taormina expert meeting on occult hepatitis B virus infection[J]. Journal of Hepatology . 2008 (4)
  • 7Erik H.C.J. Buster,Hajo J. Flink,Yilmaz Cakaloglu,Krzysztof Simon,J?rg Trojan,Fehmi Tabak,Thomas M.K. So,S. Victor Feinman,Tomasz Mach,Ulus S. Akarca,Martin Schutten,Wanda Tielemans,Anneke J. van Vuuren,Bettina E. Hansen,Harry L.A. Janssen.Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b[J]. Gastroenterology . 2008 (2)
  • 8G.K.K. Lau,T. Piratvisuth,K.X. Luo,P. Marcellin,S. Thongsawat,G. Cooksley,E. Gane,M.W. Fried,M. Popescu,J. Wu.50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B[J]. Journal of Hepatology . 2006
  • 9Harry LA Janssen,Monika van Zonneveld,Hakan Senturk,Stefan Zeuzem,Ulus S Akarca,Yilmaz Cakaloglu,Christopher Simon,Thomas MK So,Guido Gerken,Robert A de Man,Hubert GM Niesters,Pieter Zondervan,Bettina Hansen,Solko W Schalm.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial[J]. The Lancet . 2005 (9454)
  • 10D.Lavanchy.Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures[J]. Journal of Viral Hepatitis . 2004 (2)

共引文献154

同被引文献22

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部